- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
In infants and children aged 3 days to 16 years, the half-life was extremely variable, ranging from 1.7 to 12.0 hours [SmPC].
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Severe bacterial infections |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Neonatal Grey Syndrom [SmpC]
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Due to the toxic properties of chloramphenicol, it is necessary to carry out serum measurements and adjust the dose accordingly, especially in premature infants and newborns. [SmPC Chloramphenicol 1g Powder for Solution for Injection]
Grey syndrome: Toxic reactions, including deaths, have occurred in premature infants and newborns. Symptoms of grey baby syndrome occurred in the following order: abdominal distension with or without vomiting, grayish discoloration of the skin to cyanosis, circulatory collapse, often accompanied by irregular breathing, death within a few hours of the onset of symptoms.
The progression of symptoms from onset to death was accelerated with higher dose schedules. Serum levels showed unusually high concentrations of chloramphenicol (>90 µg/mL after repeated doses). Immediate discontinuation of therapy at the first sign of these symptoms may lead to complete recovery. [SmPC Chloramphenicol 1g Powder for Solution for Injection]
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Reference
- Eramol (UK) Ltd , SmPC Chloramphenicol 1 g Powder for Solution for Injection (PL49160/0001), 08/2022
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
